A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 29 Oct 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 24 Apr 2019 to 17 Sep 2019.
- 30 Jul 2019 Planned primary completion date changed from 24 Apr 2019 to 17 Sep 2019.